INTERNATIONAL JOURNAL OF HEMATOLOGY

Scope & Guideline

Delivering Cutting-Edge Findings in Hematology

Introduction

Welcome to the INTERNATIONAL JOURNAL OF HEMATOLOGY information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of INTERNATIONAL JOURNAL OF HEMATOLOGY, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0925-5710
PublisherSPRINGER JAPAN KK
Support Open AccessNo
CountryJapan
TypeJournal
Convergefrom 1991 to 2024
AbbreviationINT J HEMATOL / Int. J. Hematol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO 105-6005, JAPAN

Aims and Scopes

The International Journal of Hematology focuses on advancing the field of hematology through rigorous research and clinical studies. The journal encompasses a wide array of topics related to blood disorders, treatments, and innovative methodologies that enhance our understanding of hematological conditions.
  1. Hematological Malignancies:
    The journal extensively covers research on hematological malignancies such as leukemia, lymphoma, and myeloma, focusing on their pathophysiology, diagnosis, and treatment strategies.
  2. Bone Marrow and Stem Cell Transplantation:
    A significant portion of the research is dedicated to the methodologies and outcomes of bone marrow and stem cell transplantation, including allogeneic and autologous transplants.
  3. Coagulation Disorders:
    The journal addresses various coagulation disorders, including hemophilia and thrombocytopenia, examining both the clinical implications and therapeutic approaches.
  4. Transfusion Medicine:
    Research related to blood transfusion practices, including safety and efficacy, is a core area of focus, highlighting advancements in transfusion strategies.
  5. Genetic and Molecular Pathology:
    There is a significant emphasis on the genetic and molecular aspects of hematological diseases, including studies on mutations, gene expression, and their implications for treatment.
  6. Innovative Therapies and Clinical Trials:
    The journal highlights the latest innovations in therapy, including novel drug therapies, immunotherapies, and clinical trial outcomes that impact patient care.
  7. Patient Outcomes and Quality of Life:
    Research evaluating patient outcomes, quality of life, and psychosocial aspects of living with hematological disorders is increasingly featured, emphasizing holistic care.
The International Journal of Hematology has identified several trending and emerging themes that reflect the current advancements and interests in the field of hematology. These trends highlight the evolving nature of research priorities and the integration of innovative approaches to treatment.
  1. Precision Medicine:
    There is a marked increase in research focusing on precision medicine approaches in hematology, tailoring treatments based on genetic and molecular profiling of patients.
  2. Immunotherapy Developments:
    Studies on immunotherapy, particularly CAR-T cell therapies and bispecific antibodies, are trending, reflecting a significant shift towards utilizing the immune system to combat hematological malignancies.
  3. Real-World Evidence and Outcomes Research:
    Research that provides real-world evidence on treatment effectiveness and patient outcomes is gaining traction, emphasizing the need for practical insights beyond clinical trial settings.
  4. Molecular and Genetic Insights:
    Emerging themes include detailed molecular and genetic analyses of hematological disorders, contributing to better understanding of disease mechanisms and targeted therapies.
  5. Management of COVID-19 in Hematology Patients:
    Given the global pandemic, there is a growing interest in understanding the implications of COVID-19 on patients with hematological conditions, including treatment adaptations and outcomes.
  6. Patient-Centric Care and Quality of Life:
    Research focusing on patient-reported outcomes and quality of life measures is increasingly emphasized, reflecting a broader understanding of patient experiences and needs.

Declining or Waning

While the International Journal of Hematology has a robust focus on several key areas, some themes have shown a decline in prominence over recent years. This can indicate shifts in research interest or advancements in treatment that may render previous topics less critical.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decrease in publications focused solely on traditional chemotherapy regimens, as the field increasingly shifts towards targeted therapies and personalized medicine.
  2. Basic Hematology Research:
    Basic research in hematology, particularly studies that do not translate into clinical applications, appears to be waning as the emphasis moves towards translational and clinical research.
  3. Longitudinal Studies of Established Treatments:
    Longitudinal studies examining established treatment regimens without new intervention strategies have become less frequent, possibly due to a focus on novel therapies.
  4. Epidemiological Studies:
    The publication of epidemiological studies related to hematological conditions has declined, potentially reflecting a shift towards more clinical and therapeutic research.
  5. Animal Models in Hematology Research:
    Research utilizing animal models for hematological studies is less frequently published, as there is a growing preference for human-centric clinical research.

Similar Journals

BLOOD

Pioneering Research at the Heart of Hematology.
Publisher: AMER SOC HEMATOLOGYISSN: 0006-4971Frequency: 52 issues/year

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

ACTA HAEMATOLOGICA

Driving Excellence in Blood Science Research
Publisher: KARGERISSN: 0001-5792Frequency: 6 issues/year

ACTA HAEMATOLOGICA, published by KARGER, is a prestigious journal established in 1948, dedicated to the field of hematology and related medical sciences. With an ISSN of 0001-5792 and an E-ISSN of 1421-9662, this journal stands out with a Q2 ranking in both Hematology and Miscellaneous Medicine categories as of 2023. Researchers and professionals can benefit from its high-quality peer-reviewed articles, contributing to a more profound understanding and advancement of hematological practices. Although it does not offer open access options, ACTA HAEMATOLOGICA remains an essential resource for researchers in Switzerland and worldwide, providing critical insights and fostering discourse among academic and clinical communities. The journal's address is located in the heart of Basel, Switzerland, ensuring its robust connection to European medical research networks. With a firm commitment to excellence, this publication plays a vital role in disseminating knowledge, guiding future innovations in the field.

Hematology Transfusion and Cell Therapy

Elevating standards in cell therapy and transfusion science.
Publisher: ELSEVIERISSN: 2531-1379Frequency: 4 issues/year

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.

PEDIATRIC HEMATOLOGY AND ONCOLOGY

Elevating standards in pediatric hematology and oncology.
Publisher: TAYLOR & FRANCIS INCISSN: 0888-0018Frequency: 8 issues/year

Pediatric Hematology and Oncology, published by Taylor & Francis Inc, serves as a vital platform dedicated to the fields of hematology, oncology, and pediatrics, providing a comprehensive avenue for the dissemination of scholarly research and clinical advancements. With an ISSN of 0888-0018 and an E-ISSN of 1521-0669, this journal has successfully converged its expertise over the years from 1984 to 2024. Ranked in the Q3 category for Hematology and Oncology, alongside a Q2 ranking in Pediatrics, Perinatology, and Child Health (2023), it engages a diverse readership comprising researchers, healthcare professionals, and students eager to explore groundbreaking studies in child health and treatment methodologies. While it currently does not offer Open Access options, the journal is widely cited and recognized, particularly in its specialized fields, fostering a rich environment for dialogue and innovation in the management of pediatric hematological and oncological disorders. The journal is based in the United Kingdom at 530 Walnut Street, Ste 850, Philadelphia, PA 19106, making it an essential resource for those pursuing excellence in pediatric medical research.

Hematology-American Society of Hematology Education Program

Empowering Knowledge in Blood Disorders
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

Journal of Hematology

Exploring the Depths of Hematological Research
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

CANCER JOURNAL

Empowering Researchers to Combat Cancer Challenges.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1528-9117Frequency: 6 issues/year

CANCER JOURNAL is a leading peer-reviewed publication dedicated to the dissemination of innovative research in the fields of cancer research and oncology. Published by Lippincott Williams & Wilkins, this journal serves as an essential resource for researchers, clinicians, and students seeking to advance their understanding of cancer mechanisms, treatment strategies, and patient care. With an ISSN of 1528-9117 and an E-ISSN of 1540-336X, it boasts a respectable 2023 Q2 category ranking in both Cancer Research and Oncology, reflecting its impactful contributions to the scientific community. Although it currently does not offer open access, the journal's rigorous peer-review process ensures the publication of high-quality, relevant studies that stimulate further investigation and collaboration among professionals. Since its inception, the journal has evolved through several converged years, maintaining a steadfast commitment to addressing the complexities of cancer biology and treatment. At its core, CANCER JOURNAL aims to foster advancements in oncology, making it a vital platform for sharing pivotal findings that could transform cancer research and therapeutic practices.

Egyptian Journal of Haematology

Elevating Expertise in Blood Disorders and Transfusion Medicine
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

LEUKEMIA RESEARCH

Fostering collaboration for a brighter future in hematology.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0145-2126Frequency: 12 issues/year

Leukemia Research is a prominent academic journal dedicated to advancing the field of hematology and oncology, focusing on the latest research developments related to leukemia and other hematological disorders. Founded in 1977 and published by Pergamon-Elsevier Science Ltd in the United Kingdom, this esteemed journal has established itself as a vital resource for researchers and clinicians alike. With an impressive impact factor and categorized in the top quartiles of Cancer Research and Hematology, it provides a platform for high-quality research articles, reviews, and clinical studies that contribute to a deeper understanding of leukemia's complexities. Although not an Open Access journal, Leukemia Research ensures widespread dissemination of knowledge crucial for developing innovative treatment strategies and improving patient outcomes. Researchers, professionals, and students in the fields of hematology and oncology will find this journal an invaluable asset in staying at the forefront of leukemia research, as it prepares to expand its impact through converged years of publication extending into 2024.

Blood Science

Transforming Understanding of Blood-Related Health Issues
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2543-6368Frequency:

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.